UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 8-K
 

 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): December 6, 2010 (December 1, 2010)
 

 
SHENGTAI PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)

Delaware
 
000-51312
 
54-2155579
(State or other jurisdiction of
incorporation or organization)
 
(Commission File Number)
 
(I.R.S. Employer
Identification No.)
 
Changda Road East
Development District, Changle County
Shandong, 262400
The People’s Republic of China
(Address of principal executive offices, including zip code)
 
(86) 536-6295802
(Registrant’s telephone number, including area code)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 
 

 

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On December 1, 2010, YE Hu offered his resignation as Chief Financial Officer of Shengtai Pharmaceutical, Inc. (the “Company”), with an effective date of December 31, 2010.  The Board of Directors of the Company has accepted his resignation and is actively searching for a new Chief Financial Officer.  Yongqiang Wang, the Financial Controller of the Company, will act as principal financial officer until such time as the Board has appointed a new Chief Financial Officer.

 
2

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
SHENGTAI PHARMACEUTICALS, INC.
       
Dated: December 6, 2010
     
 
By: 
/s/ Qingtai Liu
 
 
Name: Qingtai Liu
 
Title: Chief Executive Officer
 
 
3